The DPYD gene encodes an enzyme known as dihydropyrimidine dehydrogenase (DPD). This enzyme is critical to the metabolism of fluoropyrimidine drugs such as fluorouracil/5-FU (Adrucil®), tegafur and capecitabine (Xeloda®) used in chemotherapy treatment.
Non-urgent advice: Order a DPYD test
Access more information and download order forms.
The Cambridge Genomic Laboratory provides DPYD testing for the East Genomics region. To ensure a rapid service, please submit samples directly to the laboratory by first class post or courier.
Treatment with fluoropyrimidines is generally well tolerated. However, 3-6% of patients suffer serious adverse drug reactions as a result of genetic variation in their DPYD gene which means they are unable to properly metabolise and breakdown these drugs.
Genetic testing for the common DPYD genetic variants is recommended in some cancer patients and positive results can enable dose adjustments or selection of an alternative treatment regimen.
Testing is centrally commissioned and available from the East Genomic Laboratory Hub.
Further information on DPD deficiency can be found on the Cancer Research UK website. (opens in a new tab)